PortalPublikationenCarfilzomib and dexamethasone versus eight cycles of bortezo...

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

Standard

Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. / Weisel, Katja; Majer, Istvan; DeCosta, Lucy; Oriol, Albert; Goldschmidt, Hartmut; Ludwig, Heinz; Campioni, Marco; Szabo, Zsolt; Dimopoulos, Meletios.

in: LEUKEMIA LYMPHOMA, Jahrgang 61, Nr. 1, 01.2020, S. 37-46.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Weisel, K, Majer, I, DeCosta, L, Oriol, A, Goldschmidt, H, Ludwig, H, Campioni, M, Szabo, Z & Dimopoulos, M 2020, 'Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials', LEUKEMIA LYMPHOMA, Jg. 61, Nr. 1, S. 37-46. https://doi.org/10.1080/10428194.2019.1648806

APA

Weisel, K., Majer, I., DeCosta, L., Oriol, A., Goldschmidt, H., Ludwig, H., Campioni, M., Szabo, Z., & Dimopoulos, M. (2020). Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. LEUKEMIA LYMPHOMA, 61(1), 37-46. https://doi.org/10.1080/10428194.2019.1648806

Vancouver

Weisel K, Majer I, DeCosta L, Oriol A, Goldschmidt H, Ludwig H et al. Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials. LEUKEMIA LYMPHOMA. 2020 Jan;61(1):37-46. https://doi.org/10.1080/10428194.2019.1648806

Bibtex

@article{c33f8972495443d8a45c2183b08cbdb6,
title = "Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials",
abstract = "In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. Here, matching-adjusted treatment comparison was used to compare efficacy of Kd56 with Vd, if Vd was administered for 8 cycles (Vd-8). Data from ENDEAVOR and CASTOR trials (which compared daratumumab, bortezomib, and dexamethasone with Vd-8) were used. Hazard ratios of PFS were estimated for Vd vs. Vd-8 and Kd vs. Vd-8. For cycles 1-8, risk reduction in PFS for Kd56 vs. Vd-8 was equal to that estimated in ENDEAVOR (HR: 0.53; 95% CI 0.44-0.65). Beyond eight cycles, risk reduction in PFS for Kd56 and Vd-8 was estimated to be 60% (HR: 0.40; 95% CI 0.26-0.63). The analysis suggested that PFS benefit of Kd56 over Vd increases when Vd is given for eight cycles only.",
author = "Katja Weisel and Istvan Majer and Lucy DeCosta and Albert Oriol and Hartmut Goldschmidt and Heinz Ludwig and Marco Campioni and Zsolt Szabo and Meletios Dimopoulos",
year = "2020",
month = jan,
doi = "10.1080/10428194.2019.1648806",
language = "English",
volume = "61",
pages = "37--46",
journal = "LEUKEMIA LYMPHOMA",
issn = "1042-8194",
publisher = "informa healthcare",
number = "1",

}

RIS

TY - JOUR

T1 - Carfilzomib and dexamethasone versus eight cycles of bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma: an indirect comparison using data from the phase 3 ENDEAVOR and CASTOR trials

AU - Weisel, Katja

AU - Majer, Istvan

AU - DeCosta, Lucy

AU - Oriol, Albert

AU - Goldschmidt, Hartmut

AU - Ludwig, Heinz

AU - Campioni, Marco

AU - Szabo, Zsolt

AU - Dimopoulos, Meletios

PY - 2020/1

Y1 - 2020/1

N2 - In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. Here, matching-adjusted treatment comparison was used to compare efficacy of Kd56 with Vd, if Vd was administered for 8 cycles (Vd-8). Data from ENDEAVOR and CASTOR trials (which compared daratumumab, bortezomib, and dexamethasone with Vd-8) were used. Hazard ratios of PFS were estimated for Vd vs. Vd-8 and Kd vs. Vd-8. For cycles 1-8, risk reduction in PFS for Kd56 vs. Vd-8 was equal to that estimated in ENDEAVOR (HR: 0.53; 95% CI 0.44-0.65). Beyond eight cycles, risk reduction in PFS for Kd56 and Vd-8 was estimated to be 60% (HR: 0.40; 95% CI 0.26-0.63). The analysis suggested that PFS benefit of Kd56 over Vd increases when Vd is given for eight cycles only.

AB - In ENDEAVOR, carfilzomib and dexamethasone (Kd56) demonstrated significant improvement in progression-free survival (PFS) compared with bortezomib and dexamethasone (Vd). Both agents were administered until disease progression; the EU label for Vd, however, stipulates a maximum of eight treatment cycles. Here, matching-adjusted treatment comparison was used to compare efficacy of Kd56 with Vd, if Vd was administered for 8 cycles (Vd-8). Data from ENDEAVOR and CASTOR trials (which compared daratumumab, bortezomib, and dexamethasone with Vd-8) were used. Hazard ratios of PFS were estimated for Vd vs. Vd-8 and Kd vs. Vd-8. For cycles 1-8, risk reduction in PFS for Kd56 vs. Vd-8 was equal to that estimated in ENDEAVOR (HR: 0.53; 95% CI 0.44-0.65). Beyond eight cycles, risk reduction in PFS for Kd56 and Vd-8 was estimated to be 60% (HR: 0.40; 95% CI 0.26-0.63). The analysis suggested that PFS benefit of Kd56 over Vd increases when Vd is given for eight cycles only.

U2 - 10.1080/10428194.2019.1648806

DO - 10.1080/10428194.2019.1648806

M3 - SCORING: Journal article

C2 - 31640435

VL - 61

SP - 37

EP - 46

JO - LEUKEMIA LYMPHOMA

JF - LEUKEMIA LYMPHOMA

SN - 1042-8194

IS - 1

ER -